
Martin Taphoorn
Pofessor Neuro-oncology
- Name
- Prof.dr. M.J.B. Taphoorn
- Telephone
- +31 71 526 9111
- m.j.b.taphoorn@lumc.nl
In June 2015 I started working in the LUMC as professor of neuro-oncology, in particular quality of life. I work two days a week in the LUMC, where I am a staff member at the department of neurology. In addition to neuro-oncological patient care, I chair the neuro-oncology tumor working group and lead the biweekly multidisciplinary neuro-oncology meeting. I am also involved in the training of neurology residents in the LUMC.
In June 2015 I started working in the LUMC as professor of neuro-oncology, in particular quality of life. I work two days a week in the LUMC, where I am a staff member at the department of neurology. In addition to neuro-oncological patient care, I chair the neuro-oncology tumor working group and lead the biweekly multidisciplinary neuro-oncology meeting. I am also involved in the training of neurology residents in the LUMC.
The remaining three days I am working as a neurologist/neuro-oncologist in the Haaglanden Medical Center (HMC) in The Hague, where my focus is also on neuro-oncology.
I am closely involved in the EORTC Brain Tumour Group and the EORTC Quality of Life Group, and I have been a board member in both groups. I am currently the chairman of the Grant Review Committee of the EORTC Quality of Life Group and chair of the international RANO (response assessment in neuro-oncology) PRO (patient-reported outcomes) working group.
Neuro-oncology
Neuro-oncology comprises a relatively small area within the field of oncology, in which patients have both a malignancy and a progressive neurological disease. These are mostly incurable disorders with a high morbidity due to the loss of functions of the nervous system. This has major consequences for being able to function independently in society. Personalized medicine (NWA research agenda) is therefore particularly important in this vulnerable patient population.
The professorship neuro-oncology, in particular quality of life, should lead to intensive multidisciplinary collaboration in the Leiden - The Hague area, and should become imbedded in the University Cancer Center (UKC) Leiden - The Hague. The collaboration concerns both patient care and clinical research. Regarding patient care, lateralization of gliomas occurs to the HMC (in 2016, the NFU recognized the HMC as national expertise center for gliomas), and lateralization of skull base tumors and spinal tumors to the LUMC. The quality of neuro-oncological treatments and care needs to be improved with collaboration and lateralization.
The scientific research at the LUMC and HMC focuses on the development and application of outcome measures (cognitive functioning, epilepsy, quality of life, imaging) in clinical trials and in clinical practice. This research is partly embedded in neurology (paroxysmal cerebral disorders), seeks connection/embedding in neurosurgery, radiotherapy and oncology, and has connections with radiology and medical decision making.
Outside the LUMC, an intensive research collaboration with the Erasmus MC and the EORTC has been established.
Academic career
During my training in neurology at the VUmc in Amsterdam, I conducted clinical studies in brain tumor patients to determine the effect of both the disease and its treatment on cognitive functioning and quality of life. This resulted in my thesis: 'Treatment of primary and metastatic brain tumors: beneficial and adverse effects' (September 23rd, 1994, VU University Amsterdam).
From 1995 to 2003 I supervised (pre)-clinical research in UMC Utrecht as a senior staff member at the department of neurology, conducted (multicenter) clinical studies, and I was involved in three neuro-oncological dissertations as co-supervisor.
Since 2003 I have been working part-time as a neurologist/neuro-oncologist at the HMC, where I was also head of the training program for residents of neurology from 2011 to 2015.
From 2007 to 2015 I was professor by special appointment of neuro-oncology at the Vumc for one day a week (supervisor of three neuro-oncological theses) in addition to my clinical tasks at the HMC.
From 2012 to 2016 I was board member of the European Association for Neuro-Oncology (EANO) and from 2014 to 2016 of the European CanCer Organization (ECCO). From 2009 to 2011 I was chairman of the Dutch Society for Neurology (NVN).
From 2015 I am associated to an ordinariate in the LUMC. I held my oration 'Neuro-oncology, choosing and sharing' on January 8th, 2016.
Prizes and honourable appointments
In 1984 I graduated cum laude in Medicine at the Faculty of Medicine of the University of Leiden.
For a sabbatical Neuro-Oncology (MD Anderson Houston; Memorial Sloan-Kettering New York, February - May 1998) I received a personal scholarship from the Dutch Cancer Society. Moreover, in 2006 I was nominated by the International Society for Quality of Life Research for the best article on Quality of Life research in 2005, and in 2014 I received the Abihjit Guha Award from the Indian Society for Neuro-Oncology for quality of life research in neuro-oncology.
Since January 2018 I am member of the International Advisory Board of the Lancet Oncology.
Pofessor Neuro-oncology
- Faculteit Geneeskunde
- Divisie 3
- Neurologie
- Meer, P.B. van der; Maschio, M.; Dirven, L.; Taphoorn, M.J.B.; Koekkoek, J.A.F. & Italian League Epilepsy Brain Tumo (2022), First-line levetiracetam versus enzyme-inducing antiseizure medication in glioma patients with epilepsy, Epilepsia 64(1).
- Koekkoek, J.A.F.; Meer, P.B. van der; Pace, A.; Hertler, C.; Harrison, R.; Leeper, H.E.; Forst, D.A.; Jalali, R.; Oliver, K.; Philip, J.; Taphoorn, M.J.B.; Dirven, L. & Walbert, T. (2022), Corrigendum to, Neuro-Oncology 25(1).
- Meer, P.B. van der; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2022), Management of epilepsy in brain tumor patients, Current Opinion in Oncology 34(6): 685-690.
- Meer, P.B. van der; Dirven, L.; Fiocco, M.; Vos, M.J.; Kouwenhoven, M.C.M.; Bent, M.J. van den; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2022), Effectiveness of antiseizure medication duotherapies in patients with glioma a multicenter observational cohort study, Neurology 99(10): E999-E1008.
- Caramanna, I.; Klein, M.; Bent, M. van den; Idbaih, A.; Wick, W.; Taphoorn, M.J.B.; Dirven, L.; Bottomley, A.; Reijneveld, J.C.; EORTC Quality Life Grp & EORTC Brain Tumor Grp (2022), Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients, Quality of Life Research 31(11): 3253-3266.
- Opijnen, M.P. van; Tesileanu, C.M.S.; Dirven, L.; Meer, P.B. van der; Wijnenga, M.M.J.; Vincent, A.J.P.E.; Broekman, M.L.D.; Dubbink, H.J.; Kros, J.M.; Duinen, S.G. van; Smits, M.; French, P.J.; Bent, M.J. van den; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2022), IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas, Neuro-Oncology 25(4).
- Hoang-Xuan, K.; Deckert, M.; Ferreri, A.J.M.; Furtner, J.; Perez-Larraya, J.G.; Henriksson, R.; Hottinger, A.F.; Kasenda, B.; Lefranc, F.; Lossos, A.; McBain, C.; Preusser, M.; Roth, P.; Ruda, R.; Schlegel, U.; Soffietti, R.; Soussain, C.; Taphoorn, M.J.B.; Touitou, V.; Weller, M. & Bromberg, J.E.C. (2022), European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL), Neuro-Oncology 25(1).
- Lassman, A.B.; Hoang-Xuan, K.; Polley, M.Y.C.; Brandes, A.A.; Cairncross, J.G.; Kros, J.M.; Ashby, L.S.; Taphoorn, M.J.B.; Souhami, L.; Dinjens, W.N.M.; Laack, N.N.; Kouwenhoven, M.C.M.; Fink, K.L.; French, P.J.; Macdonald, D.R.; Lacombe, D.; Won, M.; Gorlia, T.; Mehta, M.P. & Bent, M.J. van den (2022), Joint Final Report of EORTC 26951 and RTOG 9402, Journal of Clinical Oncology 40(23): 2539-+.
- Boele, F.W.; Otter, P.W.M. den; Reijneveld, J.C.; Hamer, P.C.D.; Thuijl, H.F. van; Lorenz, L.M.C.; Wesseling, P.; Lagerwaard, F.J.; Taphoorn, M.J.B.; Kouwenhoven, M.C.M.; Snijders, T.J.; Douw, L. & Klein, M. (2022), Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers, Neuro-Oncology 25(2).
- Machingura, A.; Taye, M.; Musoro, J.; Ringash, J.; Pe, M.; Coens, C.; Martinelli, F.; Tu, D.S.; Basch, E.; Brandberg, Y.; Gronvold, M.; Eggermont, A.; Cardoso, F.; Meerbeeck, J. van; Graaf, W.T.A. van der; Taphoorn, M.; Reijneveld, J.C.; Soffietti, R.; Sloan, J.; Velikova, G.; Flechtner, H.; Bottomley, A.; EORTC Quality Life Grp; Brain Tumour Breast Canc Melanoma; Lung Canc Soft Tissue Bone Sar & Head Neck Canc Genito Urinary Canc (2022), Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types, European Journal of Cancer 170: 1-9.
- Fritz, L.; Peeters, M.C.M.; Zwinkels, H.; Koekkoek, J.A.F.; Reijneveld, J.C.; Vos, M.J.; Pasman, H.R.W.; Dirven, L. & Taphoorn, M.J.B. (2022), Advance care planning (ACP) in glioblastoma patients, Neuro-Oncology Practice 9(6): 496-508.
- Kaptein, F.H.J.; Stals, M.A.M.; Kapteijn, M.Y.; Cannegieter, S.C.; Dirven, L.; Duinen, S.G. van; Eijk, R. van; Huisman, M.V.; Klaase, E.E.; Taphoorn, M.J.B.; Versteeg, H.H.; Buijs, J.T.; Koekkoek, J.A.F. & Klok, F.A. (2022), Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma, Journal of Thrombosis and Haemostasis 20(7).
- Millward, C.P.; Armstrong, T.S.; Barrington, H.; Bell, S.; Brodbelt, A.R.; Bulbeck, H.; Crofton, A.; Dirven, L.; Georgious, T.; Grundy, P.L.; Islim, A.I.; Javadpour, M.; Keshwara, S.M.; Koszdin, S.D.; Marson, A.G.; McDermott, M.W.; Meling, T.R.; Oliver, K.; Plaha, P.; Preusser, M.; Santarius, T.; Srikandarajah, N.; Taphoorn, M.J.B.; Turner, C.; Watts, C.; Weller, M.; Williamson, P.R.; Zadeh, G.; Najafabadi, A.H.Z.; Jenkinson, M.D. & EORTC BTG ICOM EANO SNO (2022), Development of 'Core Outcome Sets' for Meningioma in Clinical Studies (The COSMIC Project), BMJ Open 12(5).
- Coomans, M.; Dirven, L.; Aaronson, N.; Baumert, B.G.; Bent, M. van den; Bottomley, A.; Brandes, A.A.; Chinot, O.; Coens, C.; Gorlia, T.; Herrlinger, U.; Keime-Guibert, F.; Malmstrom, A.; Martinelli, F.; Stupp, R.; Talacchi, A.; Weller, M.; Wick, W.; Reijneveld, J.C.; Taphoorn, M.J.B.; EORTC Quality Life Grp & EORTC Brain Tumor Grp (2022), Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period, Neuro-Oncology 24(12): 2159-2169.
- Fisher, F.L.; Najafabadi, A.H.Z.; Meer, P.B. van der; Boele, F.W.; Peerdeman, S.M.; Peul, W.C.; Taphoorn, M.J.B.; Dirven, L. & Furth, W.R. van (2022), Long-term health-related quality of life and neurocognitive functioning after treatment in skull base meningioma patients, Journal of Neurosurgery 136(4): 1077-1089.
- Bady, P.; Marosi, C.; Weller, M.; Gronberg, B.H.; Schultz, H.; Taphoorn, M.J.B.; Gijtenbeek, J.M.M.; Bent, M.J. van den; Deimling, A. von; Stupp, R.; Malmstrom, A. & Hegi, M.E. (2022), DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients, Acta Neuropathologica Communications 10(1).
- Millward, C.P.; Armstrong, T.S.; Barrington, H.; Brodbelt, A.R.; Bulbeck, H.; Byrne, A.; Dirven, L.; Gamble, C.; Grundy, P.L.; Islim, A.I.; Javadpour, M.; Keshwara, S.M.; Krishna, S.T.; Mallucci, C.L.; Marson, A.G.; McDermott, M.W.; Meling, T.R.; Oliver, K.; Pizer, B.; Plaha, P.; Preusser, M.; Santarius, T.; Srikandarajah, N.; Taphoorn, M.J.B.; Watts, C.; Weller, M.; Williamson, P.R.; Zadeh, G.; Najafabadi, A.H.Z. & Jenkinson, M.D. (2022), Opportunities and challenges for the development of "core outcome sets" in neuro-oncology, Neuro-Oncology 24(7): 1048-1055.
- Koekkoek, J.A.F.; Meer, P.B. van der; Taphoorn, M.J.B. & Dirven, L. (2022), Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
- Oort, Q.; Dirven, L.; Sikkes, S.A.M.; Aaronson, N.; Boele, F.; Brannan, C.; Egeter, J.; Grant, R.; Klein, M.; Lips, I.M.; Narita, Y.; Sato, H.; Sztankay, M.; Stockhammer, G.; Talacchi, A.; Uitdehaag, B.M.J.; Reijneveld, J.C. & Taphoorn, M.J.B. (2022), Do neurocognitive impairments explain the differences between brain tumor patients and their proxies when assessing the patient's IADL?, Neuro-Oncology Practice.
- Oort, Q.; Zwinkels, H.; Koekkoek, J.A.F.; Vos, M.J.; Reijneveld, J.C.; Taphoorn, M.J.B. & Dirven, L. (2022), Is the EORTC QLQ-C30 emotional functioning scale appropriate as an initial screening measure to identify brain tumour patients who may possibly have a mood disorder?, Psycho-Oncology 31(6): 995-1002.
- (2022), The Effectiveness of Antiepileptic Drug Duotherapies in Patients With Glioma: A Multicenter Observational Cohort Study, Neurology.
- Sztankay, M.; Wintner, L.M.; Roggendorf, S.; Nordhausen, T.; Dirven, L.; Taphoorn, M.J.B.; Verdonck-de Leeuw, I.M.; Velikova, G.; Bottomley, A.; Kulis, D.; Kachel, T.; Schmidt, H. & EORTC Quality Life Grp (2021), Developing an e-learning course on the use of PRO measures in oncological practice, Supportive Care in Cancer 30.
- Noll, K.; King, A.L.; Dirven, L.; Armstrong, T.S.; Taphoorn, M.J.B. & Wefel, J.S. (2022), Neurocognition and health-related quality of life among patients with brain tumors, Hematology/Oncology Clinics of North America 36(1): 269-282.
- Meer, P.B. van der; Dirven, L.; Bent, M.J. van den; Preusser, M.; Taphoorn, M.J.B.; Ruda, R. & Koekkoek, J.A.F. (2022), Prescription preferences of antiepileptic drugs in brain tumor patients, Neuro-Oncology Practice 9(2): 105-113.
- Ma, R.C.; Taphoorn, M.J.B. & Plaha, P. (2021), Advances in the management of glioblastoma, Journal of Neurology, Neurosurgery and Psychiatry 92(10): 1103-1111.
- Bruin, M.E. de; Meer, P.B. van der; Dirven, L.; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2021), Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review, Neuro-Oncology Practice 8(5): 501-517.
- Zwinkels, H.; Dirven, L.; Bulbeck, H.J.; Grant, R.; Habets, E.J.J.; Koekkoek, J.A.F.; Oberg, I.; Oliver, K.; Pace, A.; Rooney, A.G.; Vos, M.J. & Taphoorn, M.J.B. (2021), Identification of characteristics that determine behavioral and personality changes in adult glioma patients, Neuro-Oncology Practice 8(5): 550-558.
- Linden, S.D. van der; Rutten, G.J.M.; Dirven, L.; Taphoorn, M.J.B.; Satoer, D.D.; Dirven, C.M.F.; Sitskoorn, M.M. & Gehring, K. (2021), eHealth cognitive rehabilitation for brain tumor patients, Journal of Neuro-Oncology 154(3): 315-326.
- Meulen, M. van der; Dirven, L.; Habets, E.J.J.; Bakunina, K.; Smits, M.; Achterberg, H.C.; Seute, T.; Cull, G.; Schouten, H.; Zijlstra, J.M.; Brandsma, D.; Enting, R.H.; Beijert, M.; Taphoorn, M.J.B.; Bent, M.J. van den; Issa, S.; Doorduijn, J.K. & Bromberg, J.E.C. (2021), Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients, Neuro-Oncology 23(8): 1315-1326.
- Dirven, L.; Vos, M.E.; Walbert, T.; Armstrong, T.S.; Arons, D.; Bent, M.J. van den; Blakeley, J.; Brown, P.D.; Bulbeck, H.; Chang, S.M.; Coens, C.; Gilbert, M.R.; Grant, R.; Jalali, R.; Leach, D.; Leeper, H.; Mendoza, T.; Nayak, L.; Oliver, K.; Reijneveld, J.C.; Rhun, E. le; Rubinstein, L.; Weller, M.; Wen, P.Y. & Taphoom, M.J.B. (2021), Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative, Neuro-Oncology Practice 8(4): 417-425.
- Opijnen, M.P. van; Meer, P.B. van der; Dirven, L.; Fiocco, M.; Kouwenhoven, M.C.M.; Bent, M.J. van den; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2021), The effectiveness of antiepileptic drug treatment in glioma patients, Journal of Neuro-Oncology 154.
- Klein, M.; Drijver, A.J.; Bent, M.J. van den; Bromberg, J.C.; Hoang-Xuan, K.; Taphoorn, M.J.B.; Reijneveld, J.C.; Hassel, M. ben; Vauleon, E.; Eekers, D.B.P.; Tzuk-Shina, T.; Lucas, A.; Freixa, S.V.; Golfinopoulos, V.; Gorlia, T.; Hottinger, A.F.; Stupp, R.; Baumert, B.G. & Eortc Brain Tumor Radiation Oncolo (2021), Memory in low-grade glioma patients treated with radiotherapy or temozolomide, Neuro-Oncology 23(5): 803-811.
- Meer, P.B. van der; Koekkoek, J.A.F.; Bent, M.J. van den; Dirven, L. & Taphoorn, M.J.B. (2021), Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints, Journal of Neuro-Oncology 153(1): 89-98.
- Tesileanu, C.M.S.; Vallentgoed, W.R.; Sanson, M.; Taal, W.; Clement, P.M.; Wick, W.; Brandes, A.A.; Baurain, J.F.; Chinot, O.L.; Wheeler, H.; Gill, S.; Griffin, M.; Rogers, L.; Ruda, R.; Weller, M.; McBain, C.; Reijneveld, J.; Enting, R.H.; Caparrotti, F.; Lesimple, T.; Clenton, S.; Gijtenbeek, A.; Lim, E.; Vos, F. de; Mulholland, P.J.; Taphoorn, M.J.B.; Heer, I. de; Hoogstrate, Y.; Wit, M. de; Boggiani, L.; Venneker, S.; Oosting, J.; Bovee, J.V.M.G.; Erridge, S.; Vogelbaum, M.A.; Nowak, A.K.; Mason, W.P.; Kros, J.M.; Wesseling, P.; Aldape, K.; Jenkins, R.B.; Dubbink, H.J.; Baumert, B.; Golfinopoulos, V.; Gorlia, T.; Bent, M. van den & French, P.J. (2021), Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations, Acta Neuropathologica 141(6): 945-957.
- Meer, P.B. van der; Dirven, L.; Fiocco, M.; Vos, M.J.; Kouwenhoven, M.C.M.; Bent, M.J. van den; Taphoorn, M.J.B. & Koekkoek, J.A.F. (2021), First-line antiepileptic drug treatment in glioma patients with epilepsy, Epilepsia 62(5): 1119-1129.
- Peeters, M.; Ottenheijm, G.; Bienfait, P.; Eekers, D.; Gijtenbeek, A.; Hanse, M.; Koekkoek, J.; Leeuwen, L. van; Tijssen, C.; Dirven, L. & Taphoorn, M. (2021), Glioma patient-reported outcomes: patients and clinicians, BMJ Supportive & Palliative Care.
- Roth, P.; Pace, A.; Rhun, E. le; Weller, M.; Ay, C.; Moyal, E.C.J.; Coomans, M.; Giusti, R.; Jordan, K.; Nishikawa, R.; Winkler, F.; Hong, J.T.; Ruda, R.; Villa, S.; Taphoorn, M.J.B.; Wick, W.; Preusser, M.; EANO Executive Board; EANO Executive Board & ESMO Guidelines Comm (2021), Neurological and vascular complications of primary and secondary brain tumours, Annals of Oncology 32(2): 171-182.
- Oort, Q.; Dirven, L.; Sikkes, S.A.M.; Aaronson, N.; Boele, F.; Brannan, C.; Egeter, J.; Grant, R.; Klein, M.; Lips, I.; Narita, Y.; Sato, H.; Sztankay, M.; Stockhammer, G.; Talacchi, A.; Uitdehaag, B.M.J.; Reijneveld, J.C.; Taphoorn, M.J.B. & EORTC Quality Life Grp (2021), Development of an EORTC questionnaire measuring instrumental activities of daily living (IADL) in patients with brain tumours, Quality of Life Research 30.
- Najafabadi, A.H.Z.; Meer, P.B. van der; Boele, F.W.; Taphoorn, M.J.B.; Klein, M.; Peerdeman, S.M.; Furth, W.R. van; Dirven, L. & Dutch Meningioma Consortium (2021), Long-term disease burden and survivorship issues after surgery and radiotherapy of intracranial meningioma patients, Neurosurgery 88(1): 155-164.
- Weller, M.; Bent, M. van den; Preusser, M.; Rhun, E. le; Tonn, J.C.; Minniti, G.; Bendszus, M.; Balana, C.; Chinot, O.; Dirven, L.; French, P.; Hegi, M.E.; Jakola, A.S.; Platten, M.; Roth, P.; Ruda, R.; Short, S.; Smits, M.; Taphoorn, M.J.B.; Deimling, A. von; Westphal, M.; Soffietti, R.; Reifenberger, G. & Wick, W. (2020), EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood, Nature Reviews Clinical Oncology 18.
- Pace, A.; Koekkoek, J.A.F.; Bent, M.J. van den; Bulbeck, H.J.; Fleming, J.; Grant, R.; Golla, H.; Henriksson, R.; Kerrigan, S.; Marosi, C.; Oberg, I.; Oberndorfer, S.; Oliver, K.; Pasman, H.R.W.; Rhun, E. le; Rooney, A.G.; Ruda, R.; Veronese, S.; Walbert, T.; Weller, M.; Wick, W.; Taphoom, M.J.B.; Dirven, L. & European Assoc Neuro-Oncology Pall (2020), Determining medical decision-making capacity in brain tumor patients: why and how?, Neuro-Oncology Practice 7(6): 599-612.
- Coomans, M.B.; Taphoorn, M.J.B.; Aaronson, N.K.; Baumert, B.G.; Bent, M. van den; Bottomley, A.; Brandes, A.A.; Chinot, O.; Coens, C.; Gorlia, T.; Herrlinger, U.; Keime-Guibert, F.; Malmstrom, A.; Martinelli, F.; Stupp, R.; Talacchi, A.; Weller, M.; Wick, W.; Reijneveld, J.C.; Dirven, L.; EORTC Quality Life Grp & EORTC Brain Tumor Grp (2020), Measuring change in health-related quality of life, Neuro-Oncology Practice 7(6): 668-675.
- Coomans, M.B.; Peeters, M.C.M.; Koekkoek, J.A.F.; Schoones, J.W.; Reijneveld, J.; Taphoorn, M.J.B. & Dirven, L. (2020), Research objectives, statistical analyses and interpretation of health-related quality of life data in glioma research: a systematic review, Cancers 12(12).
- Najafabadi, A.H.Z.; Meer, P.B. van der; Boele, F.W.; Taphoorn, M.J.B.; Klein, M.; Peerdeman, S.M.; Furth, W.R. van & Dirven, L. (2020), Determinants and predictors for the long-term disease burden of intracranial meningioma patients, Journal of Neuro-Oncology 151.
- Jordan, B.; Margulies, A.; Cardoso, F.; Cavaletti, G.; Haugnes, H.S.; Jahn, P.; Rhun, E. le; Preusser, M.; Scotte, F.; Taphoorn, M.J.B.; Jordan, K.; ESMO Guidelines Comm; ESMO Guidelines Comm; EONS Educ Working Grp; EONS Educ Working Grp & EANO Guideline Comm (2020), Systemic anticancer therapy-induced peripheral and central neurotoxicity, Annals of Oncology 31(10): 1306-1319.
- Wen, P.Y.; Weller, M.; Lee, E.Q.; Alexander, B.M.; Barnholtz-Sloan, J.S.; Barthel, F.P.; Batchelor, T.T.; Bindra, R.S.; Chang, S.M.; Chiocca, E.A.; Cloughesy, T.F.; DeGroot, J.F.; Galanis, E.; Gilbert, M.R.; Hegi, M.E.; Horbinski, C.; Huang, R.Y.; Lassman, A.B.; Rhun, E. le; Lim, M.; Mehta, M.P.; Mellinghoff, I.K.; Minniti, G.; Nathanson, D.; Platten, M.; Preusser, M.; Roth, P.; Sanson, M.; Schiff, D.; Short, S.C.; Taphoorn, M.J.B.; Tonn, J.C.; Tsang, J.; Verhaak, R.G.W.; Deimling, A. von; Wick, W.; Zadeh, G.; Reardon, D.A.; Aldape, K.D. & Bent, M.J. van den (2020), Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, Neuro-Oncology 22(8): 1073-1113.
- Meulen, M. van der; Bakunina, K.; Nijland, M.; Minnema, M.C.; Cull, G.; Stevens, W.B.C.; Baars, J.W.; Mason, K.D.; Beeker, A.; Beijert, M.; Taphoorn, M.J.B.; Bent, M.J. van den; Issa, S.; Doorduijn, J.K.; Bromberg, J.E.C. & Dirven, L. (2020), Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study, Annals of Oncology 31(8): 1046-1055.
- D'Urso, P.I. (2020), Letter: An Online Calculator for the Prediction of Survival in Glioblastoma Patients Using Classical Statistics and Machine Learning.
- Peeters, M.; Zwinkels, H.; Koekkoek, J.; Vos, M.; Dirven, L. & Taphoorn, M. (2020), The impact of the timing of health-related quality of life assessments on the actual results in glioma patients, Cancers 12(8).
- Armstrong, T.S.; Chang, S.M.; Jenkinson, D.; Kluetz, P. & Taphoorn, M.J.B. (2020), Glioma patient-reported outcome assessment in clinical care Reply.
- Tesileanu, C.M.S.; Dirven, L.; Wijnenga, M.M.J.; Koekkoek, J.A.F.; Vincent, A.J.P.E.; Dubbink, H.J.; Atmodimedjo, P.N.; Kros, J.M.; Duinen, S.G. van; Smits, M.; Taphoorn, M.J.B.; French, P.J. & Bent, M.J. van den (2020), Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV, Neuro-Oncology 22(4): 515-523.
- Najafabadi, A.H.Z.; Mortel, J.P.M. van de; Lobatto, D.J.; Brandsma, D.R.; Peul, W.C.; Biermasz, N.; Taphoorn, M.J.B.; Dirven, L. & Furth, W.R. van (2020), Unmet needs and recommendations to improve meningioma care through patient, partner, and health care provider input, Neuro-Oncology Practice 7(2): 239-248.
- Fritz, L.; Zwinkels, H.; Koekkoek, J.A.F.; Reijneveld, J.C.; Vos, M.J.; Dirven, L.; Pasman, H.R.W. & Taphoorn, M.J.B. (2020), Advance care planning in glioblastoma patients, Supportive Care in Cancer 28(3): 1315-1324.
- Armstrong, T.S.; Dirven, L.; Arons, D.; Bates, A.; Chang, S.M.; Coens, C.; Espinasse, C.; Gilbert, M.R.; Jenkinson, D.; Kluetz, P.; Mendoza, T.; Rubinstein, L.; Sul, J.; Weller, M.; Wen, P.Y.; Bent, M.J. van den & Taphoorn, M.J.B. (2020), Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report, The Lancet Oncology 21(2): E97-E103.
- Coens, C.; Pe, M.; Dueck, A.C.; Sloan, J.; Basch, E.; Calvert, M.; Campbell, A.; Cleeland, C.; Cocks, K.; Collette, L.; Devlin, N.; Dorme, L.; Flechtner, H.H.; Gotay, C.; Griebsch, I.; Groenvold, M.; King, M.; Kluetz, P.G.; Koller, M.; Malone, D.C.; Martinelli, F.; Mitchell, S.A.; Musoro, J.Z.; O'Connor, D.; Oliver, K.; Piault-Louis, E.; Piccart, M.; Quinten, C.; Reijneveld, J.C.; Schurmann, C.; Smith, A.W.; Soltys, K.M.; Taphoorn, M.J.B.; Velikova, G.; Bottomley, A. & Setting Int Stand Analyzing Patien (2020), International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium, The Lancet Oncology 21(2): E83-E96.
- Gehring, K.; Stuiver, M.M.; Visser, E.; Kloek, C.; Bent, M. van den; Hanse, M.; Tijssen, C.; Rutten, G.J.; Taphoorn, M.J.B.; Aaronson, N.K. & Sitskoorn, M.M. (2020), A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma, Neuro-Oncology 22(1): 103-115.
- Peeters, M.C.M.; Dirven, L.; Koekkoek, J.A.F.; Gortmaker, E.G.; Fritz, L.; Vos, M.J. & Taphoorn, M.J.B. (2020), Prediagnostic symptoms and signs of adult glioma: the patients' view, Journal of Neuro-Oncology 146(2): 293-301.
- Bottomley, A.; Reijneveld, J.C.; Koller, M.; Flechtner, H.; Tomaszewski, K.A.; Greimel, E.; Ganz, P.A.; Ringash, J.; Sasseville, M.; O'Connor, D.; Kluetz, P.G.; Campbell, A.; Tafuri, G.; Gronvold, M.; Snyder, C.; Gotay, C.; Fallowfield, D.L.; Apostolidis, K.; Wilson, R.; Stephens, R.; Oliver, K.; Schunemann, H.; Calvert, M.; Holzner, B.; Musoro, J.Z.; Wheelwright, S.; Martinelli, F.; Dueck, A.C.; Pe, M.; Coens, C.; Velikova, G.; Kulis, D.; Taphoorn, M.J.B.; Darlington, A.S.; Lewis, I.; Poll-Franse, L. van de & 5th EORTC Quality Life Canc (2019), Current state of quality of life and patient-reported outcomes research, European Journal of Cancer 121: 55-63.
- Coomans, M.B.; Dirven, L.; Aaronson, N.K.; Baumert, B.G.; Bent, M. van den; Bottomley, A.; Brandes, A.A.; Chinot, O.; Coens, C.; Gorlia, T.; Herrlinger, U.; Keime-Guibert, F.; Malmstrom, A.; Martinelli, F.; Stupp, R.; Talacchi, A.; Weller, M.; Wick, W.; Reijneveld, J.C. & Taphoorn, M.J.B. (2019), Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?, Neuro-Oncology 21(11): 1447-1457.
- Opijnen, M.P. van; Dirven, L.; Coremans, I.E.M.; Taphoorn, M.J.B. & Kapiteijn, E.H.W. (2019), The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review, International Journal of Cancer.
- Coomans, M.B.; Linden, S.D. van der; Gehring, K. & Taphoorn, M.J.B. (2019), Treatment of cognitive deficits in brain tumour patients: current status and future directions, Current Opinion in Oncology 31(6): 540-547.
- Jaspers, J.; Romero, A.M.; Hoogeman, M.S.; Bent, M. van den; Wiggenraad, R.G.J.; Taphoorn, M.J.B.; Eekers, D.B.P.; Lagerwaard, F.J.; Calduch, A.M.L.; Baumert, B.G. & Klein, M. (2019), Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial, Frontiers in Oncology 9.
- Habets, E.J.J.; Hendriks, E.J.; Taphoorn, M.J.B.; Douw, L.; Zwinderman, A.H.; Vandertop, W.P.; Barkhof, F.; Hamer, P.C.D. & Klein, M. (2019), Association between tumor location and neurocognitive functioning using tumor localization maps, Journal of Neuro-Oncology 144(3): 573-582.
- Schiff, D.; Bent, M. van den; Vogelbaum, M.A.; Wick, W.; Miller, C.R.; Taphoorn, M.; Pope, W.; Brown, P.D.; Platten, M.; Jalali, R.; Armstrong, T. & Wen, P.Y. (2019), Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus, Neuro-Oncology 21(7): 837-853.
- Coomans, M.; Dirven, L.; Aaronson, N.K.; Baumert, B.G.; Bent, M. van den; Bottomley, A.; Brandes, A.A.; Chinot, O.; Coens, C.; Gorlia, T.; Herrlinger, U.; Keime-Guibert, F.; Malmstrom, A.; Martinelli, F.; Stupp, R.; Talacchi, A.; Weller, M.; Wick, W.; Reijneveld, J.C.; Taphoorn, M.J.B.; EORTC Quality Life Grp & EORTC Brain Tumor Grp (2019), The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials, European Journal of Cancer 116: 190-198.
- Nowosielski, M.; Gorlia, T.; Bromberg, J.E.C.; Sahm, F.; Harting, I.; Kickingereder, P.; Brandes, A.A.; Taphoorn, M.J.B.; Taal, W.; Domont, J.; Idbaih, A.; Campone, M.; Clement, P.M.; Weller, M.; Fabbro, M.; Rhun, E. le; Platten, M.; Golfinopoulos, V.; Bent, M.J. van den; Bendszus, M. & Wick, W. (2019), Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study, Neurology 92(24): E2754-E2763.
- Oort, Q.; Taphoorn, M.J.B.; Sikkes, S.A.M.; Uitdehaag, B.M.J.; Reijneveld, J.C. & Dirven, L. (2019), Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors, Journal of Neuro-Oncology 143(1): 1-13.
- Dirven, L.; Reijneveld, J.C.; Taphoorn, M.J.B.; Coens, C.; El-Badawy, S.A.; Tzuk-Shina, T.; Bravo-Marques, J.; Back, M.; Stalpers, L.J.A.; Stupp, R.; Baumert, B.G. & Seidel, C. (2019), Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033, International Journal of Radiation Oncology - Biology - Physics 104(1): 90-100.
- Kerkhof, M.; Koekkoek, J.A.F.; Vos, M.J.; Bent, M.J. van den; Taal, W.; Postma, T.J.; Bromberg, J.E.C.; Kouwenhoven, M.C.M.; Dirven, L.; Reijneveld, J.C. & Taphoorn, M.J.B. (2019), Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study, Journal of Neuro-Oncology 142(3): 463-470.
- Meer, P.B. van der; Fiocco, M.; Koekkoek, J.A.F.; Taphoorn, M.J.B. & Dirven, L. (2019), Computation of antiepileptic drug retention rates in the presence of a competing risk, Seizure - European Journal of Epilepsy 67: 82-82.
- Kerkhof, M.; Koekkoek, J.A.F.; Vos, M.J.; Bent, M.J. van den; Taal, W.; Postma, T.J.; Bromberg, J.E.C.; Kouwenhoven, M.C.M.; Dirven, L.; Reijneveld, J.C. & Taphoorn, M.J.B. (2019), Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study, Journal of Neuro-Oncology 142(3).
- Bottomley, A.; Pe, M.; Sloan, J.; Basch, E.; Bonnetain, F.; Calvert, M.; Campbell, A.; Cleeland, C.; Cocks, K.; Collette, L.; Dueck, A.C.; Devlin, N.; Flechtner, H.H.; Gotay, C.; Greimel, E.; Griebsch, I.; Groenvold, M.; Hamel, J.F.; King, M.; Kluetz, P.G.; Koller, M.; Malone, D.C.; Martinelli, F.; Mitchell, S.A.; Moinpour, C.M.; Musoro, J.Z.; O'Connor, D.; Oliver, K.; Piault-Louis, E.; Piccart, M.; Pimentel, F.L.; Quinten, C.; Reijneveld, J.C.; Schurmann, C.; Smith, A.W.; Soltys, K.M.; Sridhara, R.; Taphoorn, M.J.B.; Velikova, G.; Coens, C. & Setting Int Stand Analyzing (2018), Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials, Clinical Trials 15(6): 624-630.
- Bent, M.J. van den; Klein, M.; Smits, M.; Reijneveld, J.C.; French, P.J.; Clement, P.; Vos, F.Y.F. de; Wick, A.; Mulholland, P.J.; Taphoorn, M.J.B.; Lewis, J.; Weller, M.; Chinot, O.L.; Kros, J.M.; Heer, I. de; Verschuere, T.; Coens, C.; Golfinopoulos, V.; Gorlia, T. & Idbaih, A. (2018), Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial, Lancet Oncology 19(9): 1170-1179.
- Meer, P.B. van der; Habets, E.J.J.; Wiggenraad, R.G.; Verbeek-de Kanter, A.; Nijeholt, G.J.L.A.; Zwinkels, H.; Kleins, M.; Dirven, L. & Taphoorn, M.J.B. (2018), Individual changes in neurocognitive functioning and health-related quality of life in patients with brain oligometastases treated with stereotactic radiotherapy, Journal of Neuro-Oncology 139(2): 359-368.
- Petersen, M.A.; Aaronson, N.K.; Arraras, J.I.; Chie, W.C.; Conroy, T.; Costantini, A.; Dirven, L.; Fayers, P.; Gamper, E.M.; Giesinger, J.M.; Habets, E.J.J.; Hammerlid, E.; Helbostad, J.; Hjermstad, M.J.; Holzner, B.; Johnson, C.; Kemmler, G.; King, M.T.; Kaasa, S.; Loge, J.H.; Reijneveld, J.C.; Singer, S.; Taphoorn, M.J.B.; Thamsborg, L.H.; Tomaszewski, K.A.; Velikova, G.; Verdonck-de Leeuw, I.M.; Young, T.; Groenvold, M. & European Org Res Treatment Cancer (2018), The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire, European Journal of Cancer 100: 8-16.
- Habets, E.J.J.; Taphoorn, M.J.B.; Klein, M.; Vissers, T. & Dirven, L. (2018), The level of reporting of neurocognitive outcomes in randomised controlled trials of brain tumour patients: A systematic review, European Journal of Cancer 100: 104-125.
- Meulen, M. van der; Dirven, L.; Habets, E.J.J.; Bent, M.J. van den; Taphoorn, M.J.B. & Bromberg, J.E.C. (2018), Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review, Lancet Oncology 19(8): E407-E418.
- Ediebah, D.E.; Quinten, C.; Coens, C.; Ringash, J.; Dancey, J.; Zikos, E.; Gotay, C.; Brundage, M.; Tu, D.S.; Flechtner, H.H.; Greimel, E.; Reeve, B.B.; Taphoorn, M.; Reijneveld, J.; Dirven, L.; Bottomley, A.; Canadian Canc Trials Grp & European Org Res Treatment Canc (2018), Quality of Life as a Prognostic Indicator of Survival: A Pooled Analysis of Individual Patient Data From Canadian Cancer Trials Group Clinical Trials, Cancer 124(16): 3409-3416.
- Kerkhof M., Ganeff I., Wiggenraad R. G. J., Nijeholt G. J. Lycklama a, Hammer S., Taphoorn M. J. B., Dirven L. & Vos M. J. (2018), Clinical applicability of and changes in perfusion MR imaging in brain metastases after stereotactic radiotherapy, Journal of Neuro-Oncology 138(1): 133-139.
- Hendriks, E.J.; Habets, E.J.J.; Taphoorn, M.J.B.; Douw, L.; Zwinderman, A.H.; Vandertop, W.P.; Barkhof, F.; Klein, M. & Hamer, P.C.D. (2018), Linking late cognitive outcome with glioma surgery location using resection cavity maps, Human Brain Mapping 39(5): 2064-2074.
- Taphoorn, M.J.B.; Dirven, L.; Kanner, A.A.; Lavy-Shahaf, G.; Weinberg, U.; Taillibert, S.; Toms, S.A.; Honnorat, J.; Chen, T.C.; Sroubek, J.; David, C.; Idbaih, A.; Easaw, J.C.; Kim, C.Y.; Bruna, J.; Hottinger, A.F.; Kew, Y.; Roth, P.; Desai, R.; Villano, J.L.; Kirson, E.D.; Ram, Z. & Stupp, R. (2018), Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial, JAMA Oncology 4(4): 495-504.
- Bady, P.; Kurscheid, S.; Delorenzi, M.; Gorlia, T.; Bent, M.J. van den; Hoang-Xuan, K.; Vauleon, E.; Gijtenbeek, A.; Enting, R.; Thiessen, B.; Chinot, O.; Dhermain, F.; Brandes, A.A.; Reijneveld, J.C.; Marosi, C.; Taphoorn, M.J.B.; Wick, W.; Deimling, A. von; French, P.; Stupp, R.; Baumert, B.G. & Hegi, M.E. (2018), The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033, Acta Neuropathologica 135(4): 601-615.
- Dirven, L.; Armstrong, T.S.; Blakeley, J.O.; Brown, P.D.; Grant, R.; Jalali, R.; Leeper, H.; Mendoza, T.; Nayak, L.; Reijneveld, J.C.; Rhun, E. le; Walbert, T.; Weller, M.; Wen, P.Y. & Taphoorn, M.J.B. (2018), Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative, Lancet Oncology 19(3): E173-E180.
- Fritz, L.; Dirven, L.; Reijneveld, J.C.; Koekkoek, J.A.F.; Zwinkels, H.; Stiggelbout, A.M.; Pasman, H.R.W. & Taphoorn, M.J.B. (2017), ADVANCE CARE PLANNING IN GLIOBLASTOMA PATIENTS: PHASE I OF A FEASIBILITY STUDY, Neuro-Oncology 19: 169-169.
- Taphoorn, M.J.B.; Dirven, L.; Taillibert, S.; Honnorat, J.; Chen, T.; Sroubek, J.; Paek, S.H.; Escuder, J.B.; Easaw, J.C.; David, C.A.; Kim, C.Y.; Desai, R.D.; Kew, Y.; Olivi, A.; Nicholas, G.A.; Lavy-Shahaf, G.; Kirson, E.D.; Ram, Z. & Stupp, R. (2017), EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA. RESULTS OF THE EF-14 RANDOMIZED PHASE III TRIAL, Neuro-Oncology 19: 206-206.
- Najafabadi, A.H.Z.; Peeters, M.C.M.; Lobatto, D.J.; Broekman, M.L.D.; Smith, T.R.; Biermasz, N.R.; Peerdeman, S.M.; Peul, W.C.; Taphoorn, M.J.B.; Furth, W.R. van & Dirven, L. (2017), Health-related quality of life of cranial WHO grade I meningioma patients: are current questionnaires relevant?, Acta Neurochirurgica 159(11): 2149-2159.
- Reijneveld, J.C.; Coens, C.; Taphoorn, M.J.B.; Smitt, P.S.; Clement, P.M.; Idbaih, A.; Vos, F. de; Klein, M.; Wick, W.G.; Mulholland, P.; Lewis, J.; Golfinopoulos, V.; Bottomley, A. & Bent, M. van den (2017), HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091), Neuro-Oncology 19: 203-203.
- Klein, M.; Drijver, J.; Bent, M. van den; Hoang-Xuan, K.; Taphoorn, M.J.B.; Reijneveld, J.C.; Hassel, M. ben; Eekers, D.; Tzuk, T.; Lucas, A.; Golfinopoulos, V.; Gorlia, T.; Stupp, R. & Baumert, B.G. (2017), MEMORY FUNCTIONING IN LOW-GRADE GLIOMA PATIENTS TREATED WITH EITHER RADIOTHERAPY (RT) OR TEMOZOLOMIDE (TMZ) CHEMOTHERAPY. A CORRELATIVE ANALYSIS OF EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT (EORTC) STUDY 22033-26033, Neuro-Oncology 19: 139-139.
- Klein, M.; Reijneveld, J.C.; Idbaih, A.; Taal, W.; Clement, P.M.; Vos, F. de; Wick, A.; Mulholland, P.; Taphoorn, M.J.B.; Lewis, J.; Weller, M.; Verschuere, T.; Golfinopoulos, V.; Gorlia, T. & Bent, M. van den (2017), NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS, Neuro-Oncology 19: 139-139.
- Klein, M.; Reijneveld, J.C.; Idbaih, A.; Brandes, A.; Taal, W.; Clement, P.M.; Domont, J.; Campone, M.; Taphoorn, M.J.B.; Stupp, R.; Fabbro, M.; Rhun, E. le; Dubois, F.; Weller, M.; Golfinopoulos, V.; Platten, M.; Gorlia, T.; Bent, M. van den & Wick, W. (2017), NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION, Neuro-Oncology 19: 142-142.
- Dirven, L.; Groenvold, M.; Taphoorn, M.J.B.; Conroy, T.; Tomaszewski, K.A.; Young, T.; Petersen, M.A. & EORTC Quality Life Grp (2017), Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients, Quality of Life Research 26(11): 2919-2929.
- Coomans, M.; Dirven, L.; Aaronson, N.; Baumert, B.G.; Bent, M. van den; Bottomley, A.; Brandes, A.; Chinot, O.; Coens, C.; Gorlia, T.; Herrlinger, U.; Keime-Guibert, F.; Malmstrom, A.; Martinelli, F.; Stupp, R.; Talacchi, A.; Wick, W.; Reijneveld, J.C. & Taphoorn, M.J.B. (2017), THE ADDED VALUE OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AS A PROGNOSTIC INDICATOR OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOMA PATIENTS: A META-ANALYSIS BASED ON INDIVIDUAL PATIENT DATA FROM RANDOMIZED CONTROLLED TRIALS, Neuro-Oncology 19: 207-207.
- Kerkhof, M.; Koekkoek, J.A.F.; Vos, M.J.; Bent, M. van den; Taal, W.; Postma, T.J.; Bromberg, J.E.C.; Kouwenhoven, M.; Dirven, L.; Reijneveld, J.C. & Taphoorn, M.J.B. (2017), WITHDRAWAL OF ANTIEPILEPTIC DRUGS IN GLIOMA PATIENTS AFTER LONG-TERM SEIZURE FREEDOM, Neuro-Oncology 19: 203-203.
- Weller, M.; Bent, M. van den; Tonn, J.C.; Stupp, R.; Preusser, M.; Cohen-Jonathan-Moyal, E.; Henriksson, R.; Rhun, E. le; Balana, C.; Chinot, O.; Bendszus, M.; Reijneveld, J.C.; Dhermain, F.; French, P.; Marosi, C.; Watts, C.; Oberg, I.; Pilkington, G.; Baumert, B.G.; Taphoorn, M.J.B.; Hegi, M.; Westphal, M.; Reifenberger, G.; Soffietti, R.; Wick, W. & European Assoc Neuro-Oncology EANO (2017), Evidence-based management of adult patients with diffuse glioma, Lancet Oncology 18(8): E430-E431.
- Najafabadi, A.H.Z.; Peeters, M.C.M.; Dirven, L.; Lobatto, D.J.; Groen, J.L.; Broekman, M.L.D.; Peerdeman, S.M.; Peul, W.C.; Taphoorn, M.J.B. & Furth, W.R. van (2017), Impaired health-related quality of life in meningioma patients-a systematic review, Neuro-Oncology 19(7): 897-907.
- Weller, M.; Bent, M. van den; Tonn, J.C.; Stupp, R.; Preusser, M.; Cohen-Jonathan-Moyal, E.; Henriksson, R.; Rhun, E. le; Balana, C.; Chinot, O.; Bendszus, M.; Reijneveld, J.C.; Dhermain, F.; French, P.; Marosi, C.; Watts, C.; Oberg, I.; Pilkington, G.; Baumert, B.G.; Taphoorn, M.J.B.; Hegi, M.; Westphal, M.; Reifenberger, G.; Soffietti, R.; Wick, W. & European Assoc Neuro-Oncology (2017), European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncology 18(6): E315-E329.
- Pace, A.; Dirven, L.; Koekkoek, J.A.F.; Golla, H.; Fleming, J.; Ruda, R.; Marosi, C.; Rhun, E. le; Grant, R.; Oliver, K.; Oberg, I.; Bulbeck, H.J.; Rooney, A.G.; Henriksson, R.; Pasman, H.R.W.; Oberndorfer, S.; Weller, M.; Taphoorn, M.J.B. & European Assoc Neuro-Oncology (2017), European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma, Lancet Oncology 18(6): E330-E340.
- Wijnenga, M.M.J.; Mattni, T.; French, P.J.; Rutten, G.J.; Leenstra, S.; Kloet, F.; Taphoorn, M.J.B.; Bent, M.J. van den; Dirven, C.M.F.; Veelen, M.L. van & Vincent, A.J.P.E. (2017), Does early resection of presumed low-grade glioma improve survival? A clinical perspective, Journal of Neuro-Oncology 133(1): 137-146.
- Ediebah, D.E.; Reijneveld, J.C.; Taphoorn, M.J.B.; Coens, C.; Zikos, E.; Aaronson, N.K.; Heimans, J.J.; Bottomley, A.; Klein, M. & Eortc Quality Life Dept Patient (2017), Impact of neurocognitive deficits on patient-proxy agreement regarding health-related quality of life in low-grade glioma patients, Quality of Life Research 26(4): 869-880.
- Oort, Q.; Dirven, L.; Meijer, W.; Sikkes, S.A.M.; Uitdehaag, B.M.J.; Reijneveld, J.C. & Taphoorn, M.J.B. (2017), Development of a questionnaire measuring instrumental activities of daily living ( IADL) in patients with brain tumors: a pilot study, Journal of Neuro-Oncology 132(1): 145-153.
- Koekkoek, J.A.F.; Dirven, L. & Taphoorn, M.J.B. (2017), The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma, Expert Review of Neurotherapeutics 17(2): 193-202.
- Melissa Kerkhof, Pauline L Tans‡, Rogier E Hagenbeek, Geert J Lycklama à Nijeholt, Finn K Holla, Tjeerd J Postma, Chiara S Straathof, Linda Dirven & Martin JB Taphoorn and Maaike J Vos (2017), Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients, CNS Oncology 6(4).
- Fritz, L.; Dirven, L.; Reijneveld, J.C.; Koekkoek, J.A.F.; Stiggelbout, A.M.; Pasman, H.R.W. & Taphoorn, M.J.B. (2016), Advance Care Planning in Glioblastoma Patients, Cancers 8(11).
- Bottomley, A.; Pe, M.; Sloan, J.; Basch, E.; Bonnetain, F.; Calvert, M.; Campbell, A.; Cleeland, C.; Cocks, K.; Collette, L.; Dueck, A.C.; Devlin, N.; Flechtner, H.H.; Gotay, C.; Greimel, E.; Griebsch, I.; Groenvold, M.; Hamel, J.F.; King, M.; Kluetz, P.G.; Koller, M.; Malone, D.C.; Martinelli, F.; Mitchell, S.A.; Moinpour, C.M.; Musoro, J.; O'Connor, D.; Oliver, K.; Piault-Louis, E.; Piccart, M.; Pimentel, F.L.; Quinten, C.; Reijneveld, J.C.; Schurmann, C.; Smith, A.W.; Soltys, K.M.; Taphoorn, M.J.B.; Velikova, G.; Coens, C. & Setting Int Stand Analyzing (2016), Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards, Lancet Oncology 17(11): E510-E514.
- Reijneveld, J.C.; Taphoorn, M.J.B.; Coens, C.; Bromberg, J.E.C.; Mason, W.P.; Hoang-Xuan, K.; Ryan, G.; Hassel, M. ben; Enting, R.H.; Brandes, A.A.; Wick, A.; Chinot, O.; Reni, M.; Kantor, G.; Thiessen, B.; Klein, M.; Verger, E.; Borchers, C.; Hau, P.; Back, M.; Smits, A.; Golfinopoulos, V.; Gorlia, T.; Bottomley, A.; Stupp, R. & Baumert, B.G. (2016), Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study, Lancet Oncology 17(11): 1533-1542.
- Baumert, B.G.; Hegi, M.E.; Bent, M.J. van den; Deimling, A. von; Gorlia, T.; Hoang-Xuan, K.; Brandes, A.A.; Kantor, G.; Taphoorn, M.J.B.; Hassel, M. ben; Hartmann, C.; Ryan, G.; Capper, D.; Kros, J.M.; Kurscheid, S.; Wick, W.; Enting, R.; Reni, M.; Thiessen, B.; Dhermain, F.; Bromberg, J.E.; Feuvret, L.; Reijneveld, J.C.; Chinot, O.; Gijtenbeek, J.M.M.; Rossiter, J.P.; Dif, N.; Balana, C.; Bravo-Marques, J.; Clement, P.M.; Marosi, C.; Tzuk-Shina, T.; Nordal, R.A.; Rees, J.; Lacombe, D.; Mason, W.P. & Stupp, R. (2016), Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study, Lancet Oncology 17(11): 1521-1532.
- Pe, M.; Bottomley, A.; Bonnetain, F.; Calvert, M.J.; Campbell, A.K.; Collette, L.; Dueck, A.; Devlin, N.J.; Flechtner, H.; Gotay, C.; Greimel, E.; Groenvold, M.; Hamel, J.F.; King, M.; Martinelli, F.; Mitchell, S.A.; Moinpour, C.M.; Musoro, J.; Quinten, C.; Taphoorn, M.; Coens, C. & SISAQOL Consortium (2016), A Systematic review on the choice and implementation of statistical methods in health-related quality of life data analyses in locally advanced and metastatic breast cancer randomized controlled trials (SISAQOL consortium), Quality of Life Research 25: 22-23.
- Kerkhof, M.; Ganeff, I.; Wiggenraad, R.G.J.; Nijeholt, G.J.L.A.; Hammer, S.; Taphoorn, M.J.B.; Dirven, L. & Vos, M.J. (2016), CHANGES IN PERFUSION MR IMAGING IN BRAIN METASTASES AFTER STEREOTACTIC RADIOTHERAPY, Neuro-Oncology 18: 72-73.
- Idbaih, A.; Clement, P.M.; Vos, F.Y.F.; Platten, M.; Mulholland, P.; Taphoorn, M.J.B.; Lewis, L.; Golfinopoulos, V.; Gorlia, T. & Bent, M.J. van den (2016), FIRST RESULTS OF THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1P/19Q INTACT 1ST RECURRENCE GRADE II AND III GLIOMA, Neuro-Oncology 18: 13-13.
- Najafabadi, A.H.Z.; Peeters, M.C.M.; Dirven, L.; Broekman, M.L.D.; Peul, W.C.; Taphoorn, M.J.B. & Furth, W.R. van (2016), HEALTH-RELATED QUALITY OF LIFE IN MENINGIOMA PATIENTS - A SYSTEMATIC REVIEW, Neuro-Oncology 18: 65-66.
- Wijnenga, M.M.J.; Mattni, T.; French, P.J.; Rutten, G.J.; Leenstra, S.; Kloet, F.; Taphoorn, M.J.B.; Bent, M.J. van den; Veelen, M.L.C. van & Vincent, A.J.P.E. (2016), INITIAL TREATMENT STRATEGY FOR PRESUMED LOW-GRADE GLIOMA: A PREOPERATIVE PERSPECTIVE, Neuro-Oncology 18: 12-13.
- Kerkhof, M.; Hagenbeek, R.E.; Kallen, B.F.W. van der; Nijeholt, G.J.L.A.; Dirven, L.; Taphoorn, M.J.B. & Vos, M.J. (2016), Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme, European Journal of Neurology 23(10): 1528-1533.
- Najafabadi, A.H.Z.; Dirven, L.; Broekman, M.L.D.; Peul, W.C.; Taphoorn, M.J.B. & Furth, W.R. van (2016), PATIENT-REPORTED OUTCOME MEASURES IN MENINGIOMA RESEARCH - LACK OF THE PATIENTS PERSPECTIVE, Neuro-Oncology 18: 65-65.
- Gahrmann, R.; Bent, M. van den; Holt, B. van der; Vernhout, R.; Taal, W.; Taphoorn, M.; Groot, J. de; Beerepoot, L.; Jasperse, B. & Smits, M. (2016), RADIOLOGICAL RESPONSE ASSESSMENT IN THE ERA OF BEVACIZUMAB: RANO OR VOLUMETRY? A REPORT FROM THE BELOB TRIAL., Neuro-Oncology 18: 9-9.
- Draaisma, K.; Taphoorn, M.; Weyerbrock, A.; Sanson, M.; Gorlia, T.; Golfinopoulos, V.; Kros, J.M.; Robe, P.A.; Bent, M.M.J. van den & French, J. (2016), STABILITY OF ACTIONABLE MUTATIONS IN PRIMARY AND RECURRENT GLIOBLASTOMAS, Neuro-Oncology 18: 12-12.
- Kerkhof, M.; Koekkoek, J.A.F.; Vos, M.J.; Bent, M.J. van den; Taal, W.; Postma, T.J.; Bromberg, J.E.C.; Dirven, L.; Reijneveld, J.C. & Taphoorn, M.J.B. (2016), WITHDRAWAL OF ANTIEPILEPTIC DRUGS IN GLIOMA PATIENTS AFTER LONG-TERM SEIZURE FREEDOM, Neuro-Oncology 18: 61-61.
- Wick, W.; Gorlia, T.; Bady, P.; Platten, M.; Bent, M.J. van den; Taphoorn, M.J.B.; Steuve, J.; Brandes, A.A.; Hamou, M.F.; Wick, A.; Kosch, M.; Weller, M.; Stupp, R.; Roth, P.; Golfinopoulos, V.; Frenel, J.S.; Campone, M.; Ricard, D.; Marosi, C.; Villa, S.; Weyerbrock, A.; Hopkins, K.; Homicsko, K.; Lhermitte, B.; Pesce, G. & Hegi, M.E. (2016), Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082), Clinical Cancer Research 22(19): 4797-4806.
- Zikos, E.; Coens, C.; Quinten, C.; Ediebah, D.E.; Martinelli, F.; Ghislain, I.; King, M.T.; Gotay, C.; Ringash, J.; Velikova, G.; Reeve, B.B.; Greimel, E.; Cleeland, C.S.; Flechtner, H.; Taphoorn, M.J.B.; Weis, J.; Schmucker-von Koch, J.; Sprangers, M.A.G.; Bottomley, A. & EORTC PROBE (2016), The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative, JNCI: Journal of the National Cancer Institute 108(5).
- Koekkoek, J.A.F.; Postma, T.J.; Heimans, J.J.; Reijneveld, J.C. & Taphoorn, M.J.B. (2016), Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study, Supportive Care in Cancer 24(4): 1633-1638.
- Chinot, O.L.; Taphoorn, M.J.B.; Bais, C.; Bourgon, R.; Phillips, H.S.; Abrey, L.E.; Wick, W.; Mason, W.; Henriksson, R.; Saran, F.; Nishikawa, R. & Cloughesy, T. (2016), Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient? Reply, Journal of Clinical Oncology 34(11): 1282-+.
- Armstrong, T.S.; Bishof, A.M.; Brown, P.D.; Klein, M.; Taphoorn, M.J.B. & Theodore-Oklota, C. (2016), Determining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report, Neuro-Oncology 18: 1-12.
- Habets, E.J.J.; Dirven, L.; Wiggenraad, R.G.; Verbeek-de Kanter, A.; Nijeholt, G.J.L.A.; Zwinkels, H.; Klein, M. & Taphoorn, M.J.B. (2016), Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: a prospective study, Neuro-Oncology 18(3): 435-444.
- Koekkoek, J.A.F.; Dirven, L.; Heimans, J.J.; Postma, T.J.; Vos, M.J.; Reijneveld, J.C. & Taphoorn, M.J.B. (2016), Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide, Journal of Neuro-Oncology 126(2): 347-354.
- Taphoorn, M.J.B. (2016), Similar Trials With Differing Outcomes: Reconciliation in Glioblastoma Reply, Journal of Clinical Oncology 34(3): 292-U164.
- Quinten, C.; Coens, C.; Ghislain, I.; Zikos, E.; Sprangers, M.A.G.; Ringash, J.; Martinelli, F.; Ediebah, D.E.; Maringwa, J.; Reeve, B.B.; Greimel, E.; King, M.T.; Bjordal, K.; Flechtner, H.H.; Schmucker-Von Koch, J.; Taphoorn, M.J.B.; Weis, J.; Wildiers, H.; Velikova, G.; Bottomley, A.; PROBE Clinical Grp & EORTC Clinical Grp (2015), The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients, European Journal of Cancer 51(18): 2808-2819.
- Bent, M.J. van den; Gao, Y.; Kerkhof, M.; Kros, J.M.; Gorlia, T.; Zwieten, K. van; Prince, J.; Duinen, S. van; Smitt, P.A.S.; Taphoorn, M. & French, P.J. (2015), Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas, Neuro-Oncology 17(7): 935-941.
- Hoang-Xuan, K.; Bessell, E.; Bromberg, J.; Hottinger, A.F.; Preusser, M.; Ruda, R.; Schlegel, T.; Soussain, C.; Abacioglu, U.; Cassoux, N.; Deckert, M.; Dirven, S.M.F.; Ferreri, A.J.M.; Graus, F.; Henriksson, R.; Herdinger, U.; Taphoorn, M.; Soffietti, R.; Weller, M. & European Assoc Neuro-Oncology Task (2015), Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology, Lancet Oncology 16(7): E322-E332.
- Koekkoek Johan A. F., Kerkhof Melissa, Dirven Linda, Heimans Jan J., Reijneveld Jaap C. & Taphoorn Martin J. B. (2015), Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review, Neuro-Oncology 17(7): 924-934.
- Dirven Linda, van den Bent Martin J., Bottomley Andrew, van der Meer Nelly, van der Holt Bronno, Vos Maaike J., Walenkamp Annemiek M. E., Beerepoot Laurens V., Hanse Monique C. J., Reijneveld Jaap C., Otten Aja, de Vos Filip Y. F. L., Smits Marion, Bromberg Jacoline E. C., Taal Walter & Taphoorn Martin J. B. (2015), The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial, European Journal of Cancer 51(10): 1321-1330.
- Taphoorn, M.J.B.; Henriksson, R.; Bottomley, A.; Cloughesy, T.; Wick, W.; Mason, W.P.; Saran, F.; Nishikawa, R.; Hilton, M.; Theodore-Oklota, C.; Ravelo, A. & Chinot, O.L. (2015), Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma, Journal of Clinical Oncology 33(19): 2166-+.
- Ediebah Divine E., Galindo-Garre Francisca, Uitdehaag Bernard M. J., Ringash Jolie, Reijneveld Jaap C., Dirven Linda, Zikos Efstathios, Coens Corneel, van den Bent Martin J., Bottomley Andrew & Taphoorn Martin J. B. (2015), Joint modeling of longitudinal health-related quality of life data and survival, Quality of Life Research 24(4): 795-804.
- Koekkoek Johan A. F., Dirven Linda, Heimans Jan J., Postma Tjeerd J., Vos Maaike J., Reijneveld Jaap C. & Taphoorn Martin J. B. (2015), Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide, Journal of Neurology, Neurosurgery and Psychiatry 86(4): 366-373.
- Boele, F.W.; Douw, L.; Reijneveld, J.C.; Robben, R.; Taphoorn, M.J.B.; Aaronson, N.K.; Heimans, J.J. & Klein, M. (2015), Health-Related Quality of Life in Stable, Long-Term Survivors of Low-Grade Glioma, Journal of Clinical Oncology 33(9): 1023-+.
- Brandsma D, Ulfman L, Reijneveld JC, Bracke M, Taphoorn MJB, Zwaginga JJ, Gebbink MFB, de Boer H, Koenderman L & Voest EE (2006), Constitutive integrin activation on tumor cells contributes to progression of leptomeningeal metastases, Neuro-Oncology 8(2).
- Reijneveld JC, van der Grond J, Ramos LMP, Bromberg JEC & Taphoorn MJB (2005), Proton MRS imaging in the follow-up of patients with suspected low-grade gliomas, Neuroradiology 47(12).
No relevant ancillary activities